Novel therapies for alzheimer's disease: Potentially disease modifying drugs

Research output: Chapter in Book/Report/Conference proceedingChapter


The two major neuropathologic hallmarks of Alzheimer's disease (AD) are extracellular Amyloid beta (A plaques and intracellular neurofibrillary tangles (NFTs). Several additional pathogenic mechanisms likely play a role in the pathogenesis of the disease, including inflammation oxidative damage ion disregulation and cholesterol metabolism. A number of compounds have been developed, trying to interfere with the above mentioned altered mechanisms. Conversely to symptomatic drugs available to date, these new compounds are supposed to modify pathological steps leading to AD, thus acting on the evolution of the disease. Some of them are under clinical testing, others are in preclinical phases of development. In this chapter, the main pathogenic steps leading to neurodegeneration will be discussed, together with an update of potentially disease-modifying drugs under testing.

Original languageEnglish
Title of host publicationAlzheimer's Disease Research Compendium
PublisherNova Science Publishers, Inc.
Number of pages24
ISBN (Print)9781622575107
Publication statusPublished - Jan 1 2013

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Novel therapies for alzheimer's disease: Potentially disease modifying drugs'. Together they form a unique fingerprint.

Cite this